Advanced Oncotherapy's (LON: AVO) AIM-listed shares are rising on Friday after the company announced that it has demonstrated its LIGHT technology's potential as a biologically enhanced particle therapy to treat resistant cancers.
Advanced Oncotherapy’s share price has climbed 7.79% to 41.6p so far on Friday.
The company's findings are based on research at the Mayo Clinic, which demonstrated the benefits of combining proton therapy with targeted small molecular damage repair inhibitors.
The Mayo Clinic developers named the new process for “biologically enhanced particle therapy” LEAP.
AVO believes that LEAP is a significant step forward in applying proton therapy in the treatment of cancers.
“Following the ground-breaking results published by the Mayo Clinic, LEAP represents another paradigm shift in cancer treatment,” said Jonathan Farr, Chief Clinical Officer at Advanced Oncotherapy.
“Our LIGHT system, due to its smaller beam size compared to legacy systems and its ability to deposit a greater level of radiation damage in a micro-target volume, is ideally suited to accelerate this trend and to further contribute to the development of personalised medicines,” added Farr.
Should you invest in Advanced Oncotherapy shares? Advanced Oncotherapy shares are traded on the AIM market of the London stock exchange (the alternative investment market) which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Advanced Oncotherapy shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
